title: Expression of retinoic acid receptor-beta sensitizes prostate cancer cells to growth inhibition mediated by combinations of retinoids and a 19-nor hexafluoride vitamin D3 analog.
abstract: Retinoids and analogs of vitamin D3 may achieve greater in vivo applications if the toxic side effects encountered at pharmacologically active doses could be alleviated. These seco-steroid hormones often act in concert, and therefore, we attempted to dissect these interactions by isolating combinations of receptor-selective retinoids and a potent vitamin D3 analog [1alpha,25(OH)2-16ene-23-yne-26,27,F6-19nor-D3, code name LH] that were potent inhibitors of prostate cancer cell growth at low, physiologically safer doses. Using a panel of prostate cancer cell lines representing progressively more transformed phenotypes, we found that the LNCaP cell line (least transformed) was either additively or synergistically inhibited in its clonal growth by LH and various naturally occurring and receptor-selective retinoids, the most potent combination being with a retinoic acid receptor (RAR)betagamma-selective retinoid (SR11262). The effect was not found with either PC-3 (intermediate transformation) or DU-145 (most transformed). We also undertook RT-PCR to examine the subtypes of RARs present, and we found that PC-3 and DU-145 did not express RARbeta. Stable expression of RARbeta into the RARbeta-negative PC-3 cells resulted in increased sensitivity to SR11262 and LH proportional to the amount of RARbeta expressed. This study indicates that RARbeta may play an important role in synergistically controlling cell proliferation, and expression is lost with increased prostate cancer cell transformation. Simultaneous administration of a potent vitamin D3 analog and receptor-selective retinoids may have therapeutic potential for the treatment of androgen-dependent and -independent prostate cancer.
authors.affiliation: Division of Hematology/Oncology, Cedars-Sinai Medical Center/University of California, Los Angeles School of Medicine, 90048, USA.
authors.forename: M J
authors.initials: MJ
authors.lastname: Campbell
authors.forename: S
authors.initials: S
authors.lastname: Park
authors.forename: M R
authors.initials: MR
authors.lastname: Uskokovic
authors.forename: M I
authors.initials: MI
authors.lastname: Dawson
authors.forename: H P
authors.initials: HP
authors.lastname: Koeffler
mesh_terms: D017209:Apoptosis; D002455:Cell Division / Q000187:drug effects*; D002762:Cholecalciferol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D003470:Culture Media; D015870:Gene Expression; D006801:Humans; D008297:Male; D016133:Polymerase Chain Reaction; D011471:Prostatic Neoplasms / Q000473:pathology*; D012194:RNA-Directed DNA Polymerase; D018168:Receptors, Retinoic Acid / Q000235:genetics / Q000502:physiology*; D012176:Retinoids / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: C108274:19-nor-hexafluoride vitamin D3; D003470:Culture Media; D018168:Receptors, Retinoic Acid; D012176:Retinoids; D002762:Cholecalciferol; D012194:RNA-Directed DNA Polymerase